Core Insights - The article highlights the recent milestones in research and development for Heng Rui Medicine, particularly the inclusion of KRAS G12D inhibitor HRS-4642 for advanced pancreatic cancer treatment by the National Medical Products Administration [1] - The company is also advancing its clinical pipelines, including IL-17 monoclonal antibody SHR-1314 and GLP-1/GIP dual-target agonist HRS-9531, showcasing its R&D strengths [1] - A supply disruption incident involving partner Lingli Pharmaceutical is ongoing, with Heng Rui Medicine stating it is legally assisting in the matter without disclosing specific adjustments to the partnership [1] Stock Performance - As of February 13, the A-share price closed at 58.23 yuan, down 0.87%, with a trading volume of 2.009 billion yuan; the Hong Kong stock price as of February 20 was 69.25 HKD, down 2.33% [1] - Technical analysis indicates short-term volatility, with a resistance level at 60.76 yuan and a support level at 55.95 yuan [1] - On February 13, there was a net outflow of 130 million yuan from major funds, but institutional target prices average at 76.40 yuan, indicating a potential upside of 31.20% from the current price [1] Institutional Insights - As of February 18, it was noted that the revenue from innovative drugs for Heng Rui Medicine has reached 60.66%, indicating a shift in valuation logic towards pipeline-driven growth [1] - The company has the second-largest pipeline globally with 163 self-developed projects, yet its market capitalization stands at 67 billion USD, highlighting a disparity compared to similar international pharmaceutical companies [1] - Business development (BD) is expected to become a new growth driver, with projected external licensing revenue of 6 billion yuan in 2026, although there are concerns regarding the global competitiveness of the Fast Follow strategy [1]